Solvanix Overview

Founded 2015
Status Private
Latest Deal Type Early Stage VC
Latest Deal Amount $1.63M
Latest Deal Amount
Investors 1

Solvanix General Information


Operator of a biotechnology company intended to develop and provide technology for improving stability and reducing the aggregation of fully human antibodies. The company's technology works by boosting stability and reducing aggregation of monoclonal antibodies, antibody fragments and bi-specifics, enabling biotech and pharma partners to improve their therapeutic antibodies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Primary Office
  • 384 Victoria Street
  • Darlinghurst, New South Wales 2010
  • Australia
+61 0000000000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Solvanix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 15-Jan-2015 $1.63M 00.000 Completed Startup

Solvanix Executive Team (2)

Name Title Board Seat Contact Info
Daniel Christ Ph.D Founder & Chief Scientific Officer
Philip Wallace Ph.D Head, Product and Business Development

Solvanix Board Members (2)

Name Representing Role Since
Christopher Smith Ph.D Brandon Capital Partners Board Member 000 0000
Jenny Harry Ph.D Self Board Member 000 0000

Solvanix Investors (1)

To view Solvanix‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Brandon Capital Partners Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial